| Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer DS Matassa, MR Amoroso, H Lu, R Avolio, D Arzeni, C Procaccini, ... Cell Death & Differentiation 23 (9), 1542-1554, 2016 | 164 | 2016 |
| The OPCML tumor suppressor functions as a cell surface repressor–adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer AB McKie, S Vaughan, E Zanini, IS Okon, L Louis, C de Sousa, MI Greene, ... Cancer discovery 2 (2), 156-171, 2012 | 64 | 2012 |
| The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer J Antony, E Zanini, Z Kelly, TZ Tan, E Karali, M Alomary, Y Jung, K Nixon, ... EMBO reports 19 (8), e45670, 2018 | 56* | 2018 |
| The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer J Antony, E Zanini, Z Kelly, TZ Tan, E Karali, M Alomary, Y Jung, K Nixon, ... EMBO reports 19 (8), e45670, 2018 | 38 | 2018 |
| The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR-and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer E Zanini, LS Louis, J Antony, E Karali, IS Okon, AB McKie, S Vaughan, ... Molecular Cancer Therapeutics 16 (10), 2246-2256, 2017 | 31 | 2017 |
| WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response. GH Janczar S, Nautiyal J, Xiao Y, Curry E, Sun M, Zanini E, Paige AJ Cell Death and Disease 8, e2955, 2017 | 23 | 2017 |
| Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions JR Birtley, M Alomary, E Zanini, J Antony, Z Maben, GC Weaver, ... Nature communications 10 (1), 3134, 2019 | 13 | 2019 |
| The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. Cancer Discov. 2012; 2 … AB McKie, S Vaughan, E Zanini, IS Okon, L Louis, C de Sousa, MI Greene, ... DOI: https://doi. org/10.1158/2159-8290. CD-11-0256. PMID: https://www. ncbi …, 0 | 11 | |
| Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers J Antony, E Zanini, JR Birtley, H Gabra, C Recchi Cancer Gene Therapy 28 (1), 18-26, 2021 | 9 | 2021 |
| Derazantinib, an FGFR1-3 inhibitor, inhibits CSF1R in macrophages and tumor cell lines, and synergizes with a PDL1-antibody in an FGFR-driven murine syngeneic model. M El Shemerly, L Kellenberger, E Zanini, H Lane, P McSheehy CANCER RESEARCH 82 (12), 2022 | 1 | 2022 |
| Derazantinib, an FGFR1-3 inhibitor, inhibits CSF1R in macrophages and tumor cell lines, and synergizes with a PDL1-antibody in an FGFR-driven murine syngeneic model MEL Shemerly, L Kellenberger, E Zanini, H Lane, P McSheehy Cancer Research 82 (12_Supplement), 5501-5501, 2022 | 1 | 2022 |
| 42P BAL0891: A novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) with potent single agent activity HA Lane, E Zanini, N Forster-Gross, K Litherland, F Bachmann, L Bury, ... Annals of Oncology 33, S18-S19, 2022 | 1 | 2022 |
| Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine … M El Shemerly, E Zanini, M Lecoultre, PR Walker, L Kellenberger, ... Anti-Cancer Drugs, 2023 | | 2023 |
| BAL0891: A novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division E Zanini, N Forster-Gross, F Bachmann, N Willemsen-Seegers, J de Man, ... Cancer Research 82 (12_Supplement), 5646-5646, 2022 | | 2022 |
| BAL0891: A novel dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division resulting in potent anti-cancer activity HA Lane, F Bachmann, E Zanini, P McSheehy, K Litherland, ... Cancer Research 82 (12_Supplement), 5645-5645, 2022 | | 2022 |
| Studies of the ovarian tumour suppressor protein OPCML with a view to determining its structure and understanding its role in modulating RTK signalling E Zanini Imperial College London, 2013 | | 2013 |
| The OPCML tumor suppressor binds and negatively regulates the Axl receptor tyrosine kinase, sensitizing cells to foretinib in epithelial ovarian cancer (EOC) SR Nawathe, E Zanini, G Hayward, AB McKie, H Gabra CANCER RESEARCH 72, 2012 | | 2012 |
| Abstract LB-149: The OPCML tumor suppressor binds and negatively regulates the Axl receptor tyrosine kinase, sensitizing cells to foretinib in epithelial ovarian cancer (EOC) SR Nawathe, E Zanini, G Hayward, AB McKie, H Gabra Cancer Research 72 (8_Supplement), LB-149-LB-149, 2012 | | 2012 |
| The OPCML tumor suppressor negatively regulates a specific repertoire of 5 receptor tyrosine kinases via a novel proteasomal mechanism, and its recombinant derivative is a … AB McKie, S Vaughan, I Okon, JLC Wong, E Zanini, EWF Lam, ... Cancer Research 71 (8_Supplement), 1616-1616, 2011 | | 2011 |
| 421 The OPCML tumour suppressor functions as a repressor-adaptor, negatively regulating receptor tyrosine kinases in ovarian cancer A McKie, S Vaughan, I Okon, E Zanini, F Al-Jayoosi, R Agarwal, EWF Lam, ... ejc supplements 5 (8), 108, 2010 | | 2010 |
